Cargando…
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension
Pulmonary hypertension (PH) is an enigmatic vascular disorder characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance, ultimately resulting in pressure overload, dysfunction, and failure of the right ventricle. Current medications for PH do not reverse or prevent d...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406775/ https://www.ncbi.nlm.nih.gov/pubmed/28375184 http://dx.doi.org/10.3390/jcm6040043 |
_version_ | 1783232026973831168 |
---|---|
author | Harvey, Lloyd D. Chan, Stephen Y. |
author_facet | Harvey, Lloyd D. Chan, Stephen Y. |
author_sort | Harvey, Lloyd D. |
collection | PubMed |
description | Pulmonary hypertension (PH) is an enigmatic vascular disorder characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance, ultimately resulting in pressure overload, dysfunction, and failure of the right ventricle. Current medications for PH do not reverse or prevent disease progression, and current diagnostic strategies are suboptimal for detecting early-stage disease. Thus, there is a substantial need to develop new diagnostics and therapies that target the molecular origins of PH. Emerging investigations have defined metabolic aberrations as fundamental and early components of disease manifestation in both pulmonary vasculature and the right ventricle. As such, the elucidation of metabolic dysregulation in pulmonary hypertension allows for greater therapeutic insight into preventing, halting, or even reversing disease progression. This review will aim to discuss (1) the reprogramming and dysregulation of metabolic pathways in pulmonary hypertension; (2) the emerging therapeutic interventions targeting these metabolic pathways; and (3) further innovation needed to overcome barriers in the treatment of this devastating disease. |
format | Online Article Text |
id | pubmed-5406775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54067752017-04-27 Emerging Metabolic Therapies in Pulmonary Arterial Hypertension Harvey, Lloyd D. Chan, Stephen Y. J Clin Med Review Pulmonary hypertension (PH) is an enigmatic vascular disorder characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance, ultimately resulting in pressure overload, dysfunction, and failure of the right ventricle. Current medications for PH do not reverse or prevent disease progression, and current diagnostic strategies are suboptimal for detecting early-stage disease. Thus, there is a substantial need to develop new diagnostics and therapies that target the molecular origins of PH. Emerging investigations have defined metabolic aberrations as fundamental and early components of disease manifestation in both pulmonary vasculature and the right ventricle. As such, the elucidation of metabolic dysregulation in pulmonary hypertension allows for greater therapeutic insight into preventing, halting, or even reversing disease progression. This review will aim to discuss (1) the reprogramming and dysregulation of metabolic pathways in pulmonary hypertension; (2) the emerging therapeutic interventions targeting these metabolic pathways; and (3) further innovation needed to overcome barriers in the treatment of this devastating disease. MDPI 2017-04-04 /pmc/articles/PMC5406775/ /pubmed/28375184 http://dx.doi.org/10.3390/jcm6040043 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Harvey, Lloyd D. Chan, Stephen Y. Emerging Metabolic Therapies in Pulmonary Arterial Hypertension |
title | Emerging Metabolic Therapies in Pulmonary Arterial Hypertension |
title_full | Emerging Metabolic Therapies in Pulmonary Arterial Hypertension |
title_fullStr | Emerging Metabolic Therapies in Pulmonary Arterial Hypertension |
title_full_unstemmed | Emerging Metabolic Therapies in Pulmonary Arterial Hypertension |
title_short | Emerging Metabolic Therapies in Pulmonary Arterial Hypertension |
title_sort | emerging metabolic therapies in pulmonary arterial hypertension |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406775/ https://www.ncbi.nlm.nih.gov/pubmed/28375184 http://dx.doi.org/10.3390/jcm6040043 |
work_keys_str_mv | AT harveylloydd emergingmetabolictherapiesinpulmonaryarterialhypertension AT chanstepheny emergingmetabolictherapiesinpulmonaryarterialhypertension |